Stock listing
NASDAQ:GRCE Grace Therapeutics, Inc. Stock
Home listing (NASDAQ) of Grace Therapeutics, Inc.
Follow Grace Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:GRCE
$1.71 USD -0.02 (-1.2%)
Close on Nov 20, 2026
- Day range
- $1.68 – $1.82 USDNov 20, 2026
- Volume
- 153,907 sharesNov 20, 2026
- Market cap
- $35.97M USDAt the close on Nov 20, 2026 · price × 21.04M shares outstanding
- 52-week range
- $1.64 – $5.18 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $238,253 USDMedian day 85,938 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GRCE · Home | $1.71 USD | -0.02 (-1.2%) | 153,907 | $1.71 | $1.82 | $1.68 | $1.73 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GRCE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.71 | -0.02 | -1.2% | $1.71 | $1.82 | $1.68 | 153,907 | |
| $1.73 | +0.01 | +0.6% | $1.73 | $1.76 | $1.70 | 27,707 | |
| $1.72 | -0.03 | -1.7% | $1.75 | $1.765 | $1.64 | 189,071 | |
| $1.75 | -0.06 | -3.3% | $1.83 | $1.83 | $1.73 | 49,395 | |
| $1.81 | 0.00 | 0.0% | $1.82 | $1.83 | $1.81 | 13,558 | |
| $1.81 | -0.045 | -2.4% | $1.84 | $1.875 | $1.80 | 74,170 | |
| $1.855 | -0.005 | -0.3% | $1.86 | $1.90 | $1.81 | 8,840 | |
| $1.86 | -0.005 | -0.3% | $1.84 | $1.92 | $1.84 | 27,961 | |
| $1.865 | +0.015 | +0.8% | $1.90 | $1.935 | $1.86 | 128,611 | |
| $1.85 | +0.07 | +3.9% | $1.85 | $1.90 | $1.79 | 114,878 | |
| $1.78 | -0.03 | -1.7% | $1.81 | $1.90 | $1.75 | 97,130 | |
| $1.81 | -0.03 | -1.6% | $1.849 | $1.96 | $1.78 | 64,540 | |
| $1.84 | +0.03 | +1.7% | $1.80 | $2.01 | $1.70 | 231,094 | |
| $1.81 | -0.13 | -6.7% | $1.93 | $1.95 | $1.76 | 99,539 | |
| $1.94 | 0.00 | 0.0% | $1.95 | $1.98 | $1.87 | 85,938 | |
| $1.94 | -0.07 | -3.5% | $1.99 | $2.048 | $1.882 | 75,709 | |
| $2.01 | +0.14 | +7.5% | $1.87 | $2.01 | $1.87 | 164,507 | |
| $1.87 | +0.06 | +3.3% | $1.80 | $1.90 | $1.80 | 110,459 | |
| $1.81 | -0.12 | -6.2% | $1.97 | $1.99 | $1.67 | 468,914 | |
| $1.93 | +0.015 | +0.8% | $1.91 | $1.95 | $1.88 | 47,222 | |
| $1.915 | -0.055 | -2.8% | $1.91 | $1.93 | $1.87 | 97,096 | |
| $1.97 | -0.01 | -0.5% | $1.96 | $2.02 | $1.94 | 77,141 | |
| $1.98 | +0.10 | +5.3% | $1.90 | $2.07 | $1.89 | 94,407 | |
| $1.88 | -0.01 | -0.5% | $1.89 | $1.97 | $1.822 | 90,431 | |
| $1.89 | -0.06 | -3.1% | $1.97 | $2.03 | $1.85 | 168,700 | |
| $1.95 | +0.06 | +3.2% | $1.91 | $1.97 | $1.89 | 109,300 | |
| $1.89 | -0.10 | -5.0% | $1.97 | $2.01 | $1.85 | 177,900 | |
| $1.99 | -0.03 | -1.5% | $2.00 | $2.02 | $1.97 | 52,400 | |
| $2.02 | -0.06 | -2.9% | $2.02 | $2.06 | $1.98 | 49,600 | |
| $2.08 | +0.04 | +2.0% | $2.05 | $2.09 | $2.03 | 37,800 | |
| $2.04 | -0.06 | -2.9% | $2.05 | $2.07 | $2.00 | 52,600 | |
| $2.10 | +0.03 | +1.4% | $2.06 | $2.12 | $2.05 | 84,300 | |
| $2.07 | +0.01 | +0.5% | $2.08 | $2.14 | $2.05 | 110,300 | |
| $2.06 | -0.01 | -0.5% | $2.04 | $2.08 | $2.01 | 79,000 | |
| $2.07 | +0.03 | +1.5% | $2.04 | $2.07 | $2.00 | 105,000 | |
| $2.04 | -0.11 | -5.1% | $2.11 | $2.13 | $1.98 | 344,200 | |
| $2.15 | +0.04 | +1.9% | $2.14 | $2.16 | $2.10 | 25,300 | |
| $2.11 | -0.01 | -0.5% | $2.11 | $2.15 | $2.09 | 130,200 | |
| $2.12 | 0.00 | 0.0% | $2.12 | $2.14 | $2.09 | 58,700 | |
| $2.12 | -0.04 | -1.9% | $2.14 | $2.14 | $2.10 | 80,200 | |
| $2.16 | +0.04 | +1.9% | $2.17 | $2.18 | $2.09 | 106,300 | |
| $2.12 | -0.02 | -0.9% | $2.15 | $2.15 | $2.09 | 184,700 | |
| $2.14 | +0.04 | +1.9% | $2.09 | $2.17 | $2.08 | 70,100 | |
| $2.10 | -0.01 | -0.5% | $2.12 | $2.15 | $2.08 | 109,900 | |
| $2.11 | -0.02 | -0.9% | $2.14 | $2.17 | $2.10 | 83,700 | |
| $2.13 | -0.01 | -0.5% | $2.25 | $2.25 | $2.12 | 72,200 | |
| $2.14 | -0.09 | -4.0% | $2.23 | $2.24 | $2.14 | 65,500 | |
| $2.23 | -0.06 | -2.6% | $2.29 | $2.29 | $2.17 | 66,200 | |
| $2.29 | +0.07 | +3.2% | $2.21 | $2.32 | $2.21 | 48,300 | |
| $2.22 | -0.04 | -1.8% | $2.29 | $2.46 | $2.20 | 716,000 | |
| $2.26 | +0.12 | +5.6% | $2.24 | $2.31 | $2.20 | 397,500 | |
| $2.14 | +0.02 | +0.9% | $2.12 | $2.15 | $2.07 | 224,700 | |
| $2.12 | +0.02 | +1.0% | $2.09 | $2.14 | $2.05 | 159,500 | |
| $2.10 | -0.04 | -1.9% | $2.12 | $2.19 | $2.08 | 186,300 | |
| $2.14 | 0.00 | 0.0% | $2.15 | $2.20 | $2.07 | 159,200 | |
| $2.14 | +0.04 | +1.9% | $2.19 | $2.19 | $2.10 | 49,000 | |
| $2.10 | -0.03 | -1.4% | $2.09 | $2.14 | $2.07 | 77,700 | |
| $2.13 | +0.01 | +0.5% | $2.10 | $2.14 | $2.07 | 117,300 | |
| $2.12 | -0.04 | -1.9% | $2.16 | $2.16 | $2.12 | 66,100 | |
| $2.16 | +0.01 | +0.5% | $2.10 | $2.18 | $2.10 | 82,300 | |
| $2.15 | -0.05 | -2.3% | $2.20 | $2.20 | $2.14 | 22,200 | |
| $2.20 | +0.02 | +0.9% | $2.18 | $2.22 | $2.18 | 94,443 | |
| $2.18 | -0.02 | -0.9% | $2.23 | $2.23 | $2.13 | 86,601 | |
| $2.20 | +0.06 | +2.8% | $2.15 | $2.23 | $2.15 | 75,900 | |
| $2.14 | -0.06 | -2.7% | $2.19 | $2.24 | $2.10 | 54,700 |
Splits
3 splits since 2015 · NASDAQ:GRCE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-6 | Consolidation | |
| 1-for-8 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:GRCE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update
Latest deck · Jul 28, 2026
Investor Presentation (July 2026)
Investor deck · 31 slides
Latest news
Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update
Nov 12, 2026
Closed $1.81 (-2.4%) on Nov 12, 2026
Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
Nov 5, 2026
Closed $1.78 (-1.7%) on Nov 5, 2026
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
Sep 3, 2026
Closed $2.14 (0.0%) on Sep 3, 2026
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
Aug 13, 2026
Closed $2.07 (-1.4%) on Aug 13, 2026
Grace Therapeutics Announces $10 Million Private Placement
Aug 4, 2026
Closed $2.14 (-1.8%) on Aug 5, 2026
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
Jul 28, 2026
Closed $2.25 (-2.2%) on Jul 28, 2026
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Jun 18, 2026
Closed $2.38 (+7.2%) on Jun 18, 2026
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
Apr 23, 2026
Closed $2.35 (-45.5%) on Apr 23, 2026
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
Apr 14, 2026
Closed $4.28 (+12.0%) on Apr 14, 2026
Grace Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 31 in all · newest Nov 12, 2026 · oldest 2024
- Calls
- 6 calls with a replay · 6 with a transcript · latest Feb 14, 2023
- Decks
- 10 decks · latest Jul 28, 2026
Where Grace Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GRCE · Home listing · This page | NASDAQ | United States | USD |
| BOATS:GRCE | BOATS | United States | USD |
| Lang & Schwarz:A40LEL | Lang & Schwarz | Germany | EUR |
| Frankfurt:L8S | Frankfurt | Germany | EUR |
Cash and shares
Mar 31, 2026 · Grace Therapeutics — Investor Presentation (July 2026)
- Shares outstanding
- 16,024,026
- Fully diluted
- 23,033,731
Valuation
Price/book 0.7× against a median of 2.4×: 3rd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $14.66M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.77
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Grace Therapeutics, Inc. · NASDAQ:GRCE | US$35.97M | US$14.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.77 |
| KoBioLabs, Inc. · KRX:348150 | US$38.23M | US$6.96M | n/a | 0.1× | n/a | 1.8× | −6.4% | 0.2× | n/a |
| Sprint Bioscience AB · OMXSTO:SPRINT | US$38.02M | US$28.89M | 5.1× | 2.1× | 3.7× | 4.3× | 54.4% | 0.0× | n/a |
| Theralase Technologies Inc. · TSXV:TLT | US$37.89M | US$34.22M | n/a | 61.1× | n/a | 7.9× | −472.5% | 0.0× | 0.75 |
| Connect Biopharma Holdings Limited · NASDAQ:CNTB | US$37.15M | US$18.16M | n/a | 4.9× | n/a | 3.1× | n/a | 0.0× | 0.93 |
| Coiled Therapeutics PLC · LSE:COIL | US$37.13M | US$30.46M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| TaiRx, Inc. · TPEX:6580 | US$37.07M | US$28.61M | n/a | 33.8× | n/a | 3.3× | −793.3% | 0.0× | n/a |
| Pliant Therapeutics, Inc. · NASDAQ:PLRX | US$36.89M | −US$104.2M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.06 |
| Arovella Therapeutics Limited · ASX:ALA | US$36.01M | US$26.51M | n/a | n/a | n/a | 3.8× | n/a | 0.0× | n/a |
| Cantargia AB · OMXSTO:CANTA | US$35.59M | US$13.85M | 2.2× | 0.5× | 0.9× | 1.4× | 52.8% | 0.0× | n/a |
| Cue Biopharma, Inc. · NASDAQ:CUE | US$34.69M | −US$23.25M | n/a | −0.7× | n/a | 0.9× | −580.0% | 0.0× | 2.35 |
| Median of the others | US$37.10M | US$22.33M | 3.6× | 2.1× | 2.3× | 2.4× | −239.4% | 0.0× | 1.00 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.85 USD · Analysts' mean
- EPS, year to Mar 2027
- -0.76 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Prashant Kohli | Chief Executive Officer and Director |
| Amresh Kumar | Vice President Program Management |
| R. Loch Macdonald | Chief Medical Officer |
| Robert J. DelAversano | Principal Financial Officer and Principal Accounting Officer |
Board
| Director | Role |
|---|---|
| Vimal Kavuru | Chair of the Board |
| Brian Davis | Director |
| Edward Neugeboren | Director |
| George Kottayil | Director |
| Prashant Kohli | Chief Executive Officer and Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Acasti Pharma, Inc. (ACST) Q3 2023 Earnings Call | Tue, Feb 14, 2023 · 1:00 PM ET | Replay |
| Acasti Pharma, Inc. (ACST) Q2 2023 Earnings Call | Mon, Nov 14, 2022 · 1:00 PM ET | Replay |
| Acasti Pharma, Inc. (ACST) Q1 2023 Earnings Call | Thu, Aug 11, 2022 · 1:00 PM ET | Replay |
| Acasti Pharma, Inc. (ACST) Q4 2022 Earnings Call | Tue, Jun 21, 2022 · 1:00 PM ET | Replay |
| Acasti Pharma, Inc. (ACST) Q3 2022 Earnings Call | Mon, Feb 14, 2022 · 1:00 PM ET | Replay |
| Acasti Pharma, Inc. (ACST) Q2 2022 Earnings Call | Wed, Nov 10, 2021 · 1:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Nov 12, 2026 · Before open | −2.4% |
| Q1 2027 | Aug 13, 2026 · Before open | −1.4% |
| Q4 2026 | Jun 18, 2026 · Before open | +7.2% |
| Q3 2026 | Feb 12, 2026 · Before open | −1.7% |
| Q2 2026 | Nov 13, 2025 · Before open | +2.3% |
| Q1 2026 | Aug 12, 2025 · Before open | +3.5% |
| Q4 2025 | Jun 23, 2025 | 0.0% |
| Q3 2025 | Feb 17, 2025 | −0.9% |
| Q2 2025 | Nov 13, 2024 · Before open | −4.4% |
| Q1 2025 | Aug 9, 2024 · Before open | −3.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | Jun 21, 2024 | +1.6% |
| Q3 2024 | Feb 12, 2024 · Before open | +6.5% |
| Q2 2024 | Nov 13, 2023 · Before open | −3.1% |
| Q1 2024 | Aug 11, 2023 · Before open | 0.0% |
| Q4 2023 | Jun 23, 2023 | −5.3% |
| Q3 2023 | Feb 14, 2023 · Before open | +3.1% |
| Q2 2023 | Nov 14, 2022 | 0.0% |
| Q1 2023 | Aug 11, 2022 | +7.9% |
| Q4 2022 | Jun 21, 2022 · Before open | 0.0% |
| Q3 2022 | Feb 14, 2022 · Before open | +7.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 31 slides | Jul 28, 2026 |
| Investor Presentation (April 2026) | Investor deck | 32 slides | Apr 27, 2026 |
| Investor Presentation (2026) | Investor deck | 29 slides | 2026 |
| Investor Presentation (November 2025) | Investor deck | 31 slides | Nov 13, 2025 |
| Investor Presentation (March 2025) | Investor deck | 30 slides | Mar 3, 2025 |
| Investor Presentation (February 2025) | Investor deck | 35 slides | Feb 10, 2025 |
| Acasti Pharma — Investor Presentation (April 2024) | Investor deck | 18 slides | Apr 1, 2024 |
| Acasti Pharma — Merger or Acquisition (May 2021) | Merger or acquisition | 21 slides | May 7, 2021 |
| Acasti Pharma — IPO Roadshow (November 2017) | IPO roadshow | 46 slides | Nov 24, 2017 |
| Acasti Pharma — Shareholder Meeting (June 2016) | Shareholder meeting | 4 slides | Jun 14, 2016 |
Financings
| Raise | Date |
|---|---|
| Private placement of private placement financing Update: about US$10M · US$2.1 a share · Craig-Hallum Dealers: Craig-Hallum (lead) Use of proceeds: Support the manufacturing and regulatory work needed to advance GTx-104 | Aug 13, 2026 |
| Warrant exercise of common stock on exercise of common warrants Closed: US$4M raised · US$3.003 a share | Oct 23, 2025 |
| Private placement of securities with accompanying warrants Closed: US$15M raised Buyers: Nantahala Capital (co-led the financing); ADAR1 Partners, LP (co-led the financing); Stonepine Capital Management Use of proceeds: Pre-commercial planning, commercial team build out and product launch of GTx-104 if approved | Feb 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 100.0M | 196.0K | ||||
| Cost of revenue | 7.00K | 7.00K | 11.0K | 124.0K | 0 | 76.0K | 3.12M | 2.68M | 2.57M | |
| Gross profit | -7.00K | -7.00K | -11.0K | -124.0K | 0 | 189.4K | -3.12M | -2.68M | -2.57M | |
| Research and development | 2.40M | 9.51M | 4.68M | 9.97M | 5.56M | 4.17M | 16.0M | 29.4M | 12.1M | 7.18M |
| Selling, general and administrative | 8.66M | 10.2M | 9.02M | 10.9M | 12.1M | 8.70M | 11.6M | 3.80M | 3.12M | |
| Operating income | -11.1M | -16.7M | -12.9M | -52.2M | -15.6M | -16.4M | -24.4M | -34.4M | -15.3M | -10.5M |
| Depreciation and amortization | 7.00K | 7.00K | 11.0K | 124.0K | 0 | 143.0K | 410.0K | 384.0K | 2.07M | 2.57M |
| EBITDA | -11.1M | -16.7M | -12.8M | -52.0M | -15.6M | -16.3M | -24.0M | -34.0M | -13.2M | -7.95M |
| Interest expense | 331.6K | 414.2K | 1.05M | 371.6K | 54.4K | |||||
| Income before tax | -9.49M | -12.8M | -14.7M | -52.0M | -10.5M | -19.7M | -25.5M | -39.4M | -16.7M | -10.7M |
| Income tax | -1.70M | -3.20M | -1.83M | -9.54M | -648.0K | 0 | 0 | 0 | -121.1K | |
| Net income | -7.79M | -9.57M | -12.9M | -42.4M | -9.82M | -19.7M | -25.5M | -39.4M | -16.7M | -10.6M |
| Earnings per share, basic | -0.47 | -0.79 | -1.35 | -5.71 | -0.27 | -1.33 | -0.30 | -0.73 | -45.71 | -45.67 |
| Earnings per share, diluted | -0.47 | -0.79 | -1.35 | -5.71 | -0.27 | -1.33 | -0.30 | -0.73 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.0M | 22.1M | 23.0M | 27.9M | 30.3M | 50.9M | 14.2M | 16.9M | 6.37M | |
| Short-term investments | 0 | 15.0K | 13.3M | 9.79M | 9.79M | 8.89M | ||||
| Receivables | 20.0K | 126.0K | 722.0K | 802.0K | 548.0K | 530.0K | 546.0K | 1.19M | 759.3K | 206.2K |
| Inventory | 1 | |||||||||
| Current assets | 17.4M | 22.7M | 24.0M | 29.3M | 45.3M | 62.4M | 18.5M | 28.0M | 7.35M | 10.2M |
| Property, plant and equipment | 8.00K | 15.0K | 24.0K | 104.0K | 20.9M | 1.91M | 2.11M | |||
| Goodwill | 8.14M | 8.14M | 8.14M | 8.14M | 13.0M | 0 | ||||
| Total assets | 66.7M | 72.0M | 73.3M | 79.1M | 128.6M | 62.5M | 22.9M | 36.9M | 17.8M | 25.5M |
| Accounts payable | 702.0K | 601.0K | 1.01M | 1.24M | 3.16M | 144.5K | 2.42M | 3.05M | 2.65M | |
| Current liabilities | 2.15M | 1.93M | 1.68M | 3.41M | 3.26M | 1.58M | 7.39M | 13.7M | 5.19M | 2.14M |
| Total debt | 485.0K | 295.0K | 108.0K | 207.8K | 1.36M | 1.25M | 1.41M | |||
| Total liabilities | 2.76M | 5.38M | 11.6M | 11.2M | 20.4M | 6.80M | 9.86M | 25.9M | 11.4M | 3.76M |
| Shareholders' equity | 63.9M | 66.6M | 61.7M | 68.0M | 108.3M | 55.7M | 13.0M | 11.0M | 6.37M | 21.7M |
| Shares outstanding | 16.0M | 13.7M | 9.40M | 7.44M | 44.3M | 44.6M | 44.4M | 208.4M | 364.3K | 231.1K |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.87M | -14.9M | -12.3M | -15.9M | -17.2M | -14.3M | -23.0M | -24.8M | -9.69M | -6.94M |
| Capital spending | 0 | 0 | -22.0K | -17.0K | 0 | -86.7K | -450.9K | -534.0K | -352.3K | -2.57M |
| Free cash flow | -8.87M | -14.9M | -12.4M | -15.9M | -17.2M | -18.1M | -32.9M | -25.3M | -10.0M | -9.51M |
| Cash from investing | 0 | 0 | 104.0K | 13.2M | -3.52M | -9.86M | 8.14M | -9.44M | -318.3K | 6.85M |
| Cash from financing | 3.71M | 14.0M | 7.36M | 304.0K | 0 | 59.5M | 13.2M | 45.7M | 8.83M | 7.00M |
| Share buybacks | -31.0K | |||||||||
| Change in cash | -5.16M | -872.0K | -4.87M | -2.46M | -20.6M | 36.7M | -2.63M | 10.4M | -1.20M | -2.98M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Oct 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 18, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 1, 2026 | Other filings | SEC |
| S-3 · Registration statement | Aug 24, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| D | Aug 10, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Jul 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 28, 2026 | Current report | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| 8-K · Current report | Jun 18, 2026 | Results | SEC |
| 10-K · Annual report | Jun 18, 2026 | Annual report | SEC |
| 8-K · Current report | Jun 5, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| 8-K · Current report | Apr 23, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Feb 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 10-Q/A · Quarterly report, amended | Nov 17, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| 8-K · Current report | Sep 12, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Jul 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Results | SEC |
| 10-K · Annual report | Jun 23, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 12, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 11, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 10, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| D | Feb 25, 2025 | Other filings | SEC |
| 10-Q/A · Quarterly report, amended | Feb 18, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Feb 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 10, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2025 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2024 | Current report | SEC |
| 8-K · Current report | Oct 25, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 16, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 16, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Oct 8, 2024 | Offer document | SEC |
| S-8 POS | Oct 8, 2024 | Offer document | SEC |
| S-8 POS | Oct 8, 2024 | Offer document | SEC |
| S-8 POS | Oct 8, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Oct 8, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Oct 8, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 7, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 30, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 25, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 6, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 16, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Aug 7, 2024 | Meeting notice | SEC |
| 424B3 · Prospectus | Aug 7, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 5, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 31, 2024 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jul 31, 2024 | Offer document | SEC |
| 3/A · Initial statement of ownership, amended | Jul 11, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jul 10, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jul 9, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jul 3, 2024 | Other filings | SEC |
| S-4 · Registration statement | Jun 27, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 8-K · Current report | Jun 21, 2024 | Results | SEC |
| 10-K · Annual report | Jun 21, 2024 | Annual report | SEC |
| 4/A · Change in ownership, amended | May 10, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Apr 9, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Feb 12, 2024 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Jan 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2023 | Current report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2023 | Material contract | SEC |
| 3 · Initial statement of ownership | Oct 20, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 20, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 20, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Oct 17, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Oct 16, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Oct 12, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 12, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 11, 2023 | Meeting outcome | SEC |
| D | Oct 10, 2023 | Other filings | SEC |
| S-3 · Registration statement | Oct 6, 2023 | Offer document | SEC |
| 4 · Change in ownership | Sep 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2023 | Material contract | SEC |
| 4 · Change in ownership | Sep 5, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 25, 2023 | Offer document | SEC |
| DEFA14A · Additional proxy material | Aug 25, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 25, 2023 | Meeting notice | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 24, 2023 | Current report | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 7, 2023 | Current report | SEC |
| 8-K · Current report | Jul 5, 2023 | Current report | SEC |
| 8-K · Current report | Jun 23, 2023 | Results | SEC |
| 10-K · Annual report | Jun 23, 2023 | Annual report | SEC |
| 3 · Initial statement of ownership | May 26, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 18, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 18, 2023 | Insider trade | SEC |
| 8-K · Current report | May 11, 2023 | Management or board change | SEC |
| 8-K · Current report | Apr 5, 2023 | Management or board change | SEC |
| 8-K · Current report | Mar 31, 2023 | Management or board change | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 8-K · Current report | Feb 22, 2023 | Current report | SEC |
| 8-K · Current report | Feb 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Feb 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jan 25, 2023 | Current report | SEC |
| 8-K · Current report | Dec 28, 2022 | Current report | SEC |
| 8-K · Current report | Dec 22, 2022 | Current report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2022 | Insider trade | SEC |
This page holds 200 of 599 filings. Open Filings
Cap table
Built by 6ix from Grace Therapeutics, Inc.’s releases · as of Nov 11, 2026
- Common shares
- 21,035,930
- Fully diluted
- 21,035,930
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 21,035,930 | Nov 11, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 21,035,930 |
| Sep 30, 2026 | 21,035,930 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brian Davis Other companies: Verrica Pharmaceuticals Inc. (Chief Financial Officer · Oct 18, 2019 – Jun 4, 2021 · Past); Strongbridge Biopharma plc (Chief Financial Officer · Jan 1, 2018 – Feb 20, 2019 · Past); Tengion Inc (Chf. Fin. Offr, VP Fin. · Aug 1, 2010 – Mar 4, 2013 · Past) | Director · Since at least Oct 10, 2023 |
| John Canan Other companies: Terex Corporation (Director · Since at least Feb 2, 2026); Rev Group Inc (Director · Since at least Dec 11, 2020) | Director · Nov 12, 2021 – Sep 28, 2022 · Past |
| Brian J Groch Other companies: Veru Inc. (Chief Commercial Officer · Jan 1, 2017 – Dec 14, 2017 · Past) | CHIEF COMMERCIAL OFFICER · Apr 1, 2020 – Apr 1, 2020 · Past |
| Donald Olds Other companies: Retension Pharmaceuticals, Inc. (Director · Since at least Oct 13, 2026) | Director · Apr 1, 2020 – Aug 31, 2023 · Past |
| Edward Neugeboren Other companies: Matinas BioPharma Holdings, Inc. (Board Member · Since at least Mar 11, 2025) | Director · Since at least Oct 10, 2023 |
| Robert J. DelAversano Other companies: U.S. Gold Corp. (See Remarks · Dec 22, 2017 – Apr 10, 2018 · Past) | Principal Financial Officer and Principal Accounting Officer · Since at least Jan 5, 2024 |
| Amresh Kumar | Vice President Program Management · Since at least May 8, 2023 |
| Brian D Ford | CHIEF FINANCIAL OFFICER · Sep 14, 2020 – Jun 22, 2022 · Past |
| Carrie D'Andrea | VP Clinical Operations · May 8, 2023 – Apr 14, 2025 · Past |
| George Kottayil | Director · Since at least Nov 10, 2021 |
All 18 people
| Person | Seat |
|---|---|
| Janelle D'Alvise | PRESIDENT & CEO, Director · Apr 1, 2020 – Jun 22, 2022 · Past |
| Jean-Francois Boily | VICE-PRESIDENT, FINANCE · Apr 1, 2020 – Apr 1, 2020 · Past |
| Pierre Lemieux | COO, Canada & CSO · Apr 1, 2020 – Jun 22, 2022 · Past |
| Prashant Kohli | Chief Executive Officer and Director · Since at least Sep 9, 2022 |
| R. Loch Macdonald | Chief Medical Officer · Since at least May 8, 2023 |
| Roderick Noel Carter | Director · Apr 1, 2020 – Nov 12, 2021 · Past |
| Vimal Kavuru | Chair of the Board · Since at least Aug 27, 2021 |
| William A Haseltine | Director · Aug 27, 2021 – Nov 12, 2021 · Past |
Log in to ask 6ix AI your own questions about Grace Therapeutics, Inc.